Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 785-786, 2004; 10.1373/clinchem.2003.025510
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Becker, S.
Right arrow Articles by Solomayer, E.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, S.
Right arrow Articles by Solomayer, E.-F.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2004;50:785-786.)
© 2004 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Time Is an Important Factor when Processing Samples for the Detection of Disseminated Tumor Cells in Blood/Bone Marrow by Reverse Transcription-PCR

Sven Becker1,a, Graziella Becker-Pergola1, Tanja Fehm1, Diethelm Wallwiener1 and Erich-Franz Solomayer1

1 Department of Obstetrics, and Gynecology, University of Tübingen, Calwerstrasse 7, 72070 Tübingen, Germany

aAuthor for correspondence. Fax 49-7071-295424; e-mail sven.becker@med.uni-tuebingen.de.

The first 20% of the full text of this article appears below.


To the Editor:

Despite histopathologic evidence of tumor-free margins, many breast cancer patients suffer from recurrence of their disease. This may reflect the presence of disseminated, premetastatic tumor cells at the time of initial diagnosis and therapy. The detection of disseminated tumor cells in bone marrow/blood has been associated with increased mortality in breast cancer patients (1). Reverse transcription-PCR (RT-PCR) for cytokeratin 19 (CK19) may be a useful alternative or complement to immunocytochemical detection (2). Unfortunately, results of RT-PCR studies vary widely. The reasons for this are conceptual as well as technical.

Because RNAses in samples can degrade RNA before analysis, we measured mRNA by RT-PCR in 15 sets of four samples each that were processed at different time points after collection and addition of . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.